Abstract
Heart ion-channel function and expression are continuously being regulated on the basis of the hemodynamic state of the cardiovascular system, the neurohumoral milieu and the properties of the ongoing ionic fluxes. These homeostatic forces act through multiple mechanisms at transcriptional, translational and post-translational levels. Of clinical importance is the fact that with adverse stress these regulatory mechanisms can produce arrhythmogenic channel remodelling. Although a great deal is known about the functionality of ion channels and the generation of the action potential, much less is known about the underlying controlling mechanisms and how these become derailed during disease. microRNA-mediated posttranscriptional control is a very recent addition to cardiovascular biology. Here, we outline discoveries pertaining to these new regulators and how they might be involved in cardiac electrophysiology and pathology.
Keywords: microRNA, cardiac electrophysiology, ion channels, arrhythmogenesis, conduction
Current Drug Targets
Title: MicroRNAs and Cardiac Conduction
Volume: 11 Issue: 8
Author(s): M.V.G. Latronico and G. Condorelli
Affiliation:
Keywords: microRNA, cardiac electrophysiology, ion channels, arrhythmogenesis, conduction
Abstract: Heart ion-channel function and expression are continuously being regulated on the basis of the hemodynamic state of the cardiovascular system, the neurohumoral milieu and the properties of the ongoing ionic fluxes. These homeostatic forces act through multiple mechanisms at transcriptional, translational and post-translational levels. Of clinical importance is the fact that with adverse stress these regulatory mechanisms can produce arrhythmogenic channel remodelling. Although a great deal is known about the functionality of ion channels and the generation of the action potential, much less is known about the underlying controlling mechanisms and how these become derailed during disease. microRNA-mediated posttranscriptional control is a very recent addition to cardiovascular biology. Here, we outline discoveries pertaining to these new regulators and how they might be involved in cardiac electrophysiology and pathology.
Export Options
About this article
Cite this article as:
Latronico M.V.G. and Condorelli G., MicroRNAs and Cardiac Conduction, Current Drug Targets 2010; 11 (8) . https://dx.doi.org/10.2174/138945010791591340
DOI https://dx.doi.org/10.2174/138945010791591340 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Peroxynitrite in the Cardiovascular Dysfunction of Septic Shock
Current Vascular Pharmacology The Therapeutic Potential of Hepatocyte Growth Factor for Myocardial Infarction and Heart Failure
Current Pharmaceutical Design Updated Electrocardiographic Classification of Acute Coronary Syndromes
Current Cardiology Reviews Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy Indications for Heart Transplantation in Congenital Heart Disease
Current Cardiology Reviews Vitamin E in Oxidant Stress-Related Cardiovascular Pathologies: Focus on Experimental Studies
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery The Cardiovascular and Cardiac Actions of Ecstasy and its Metabolites
Current Pharmaceutical Biotechnology Alcohol Use and Cataract
Current Drug Abuse Reviews Association of Viruses in the Development of Cardiovascular Diseases
Current Pharmaceutical Design Controlled Release of Growth Factors for Regenerative Medicine
Current Pharmaceutical Design Biological Activities of Receptor-interacting Protein 140 in Adipocytes and Metabolic Diseases
Current Diabetes Reviews New Perspective Therapy of Breast Cancer Based on Selective Dopamine Receptor D2 Agonist and Antagonist Effects on MCF-7 Cell Line
Recent Patents on Anti-Cancer Drug Discovery Circadian Rhythm in Cytokines Administration
Mini-Reviews in Medicinal Chemistry Cellular Senescence in Cardiovascular Diseases: Potential Age-Related Mechanisms and Implications for Treatment
Current Pharmaceutical Design Endothelin Receptor Antagonists: Another Potential Alternative for Cardiovascular Diseases
Current Drug Targets - Cardiovascular & Hematological Disorders Editorial [Hot Topic: Pathogenesis and Treatment of Diabetic Complications,Retinopathy, Nephropathy and Cardiomyopathy (Executive Editor: J.L. Wilkinson-Berka)]
Current Pharmaceutical Design Mitochondrial and Nuclear Genes of Mitochondrial Components in Cancer
Current Genomics Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets Mitochondrial Toxicity in HAART: An Overview of In Vitro Evidence
Current Pharmaceutical Design